13C urea breath test for predicting resistance to therapy in Helicobacter pylori infection

Cremonini, F.; Zocco, M.A.; Armuzzi, A.; Bartolozzi, Francesco; Padalino, C.; De, Smith; Danese, Silvio; Gabrielli, María Gabriella; Colasanti, S.; Pola, Paolo; Gasbarrini, Giovanni; Gasbarrini, Antonio

doi:10.1016/s1590-8658(00)80530-7

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DOB is increasingly recognized as a quantitative measure of H. pylori gastric load [40]. The bacterial urease activity, which correlates with DOB values, mainly depends on the overall bacterial load [41] and some studies have suggested that high DOB values are associated with a high bacterial load in the stomach [42–44] as well as with H. pylori virulence factors, such as CagA [45, 46]. The data on GutGard indicates that the H. pylori load was significantly decreased in GutGard treated subjects as compared to placebo treatment.…”

Section: Discussionmentioning

confidence: 99%

Effect of GutGard in the Management ofHelicobacter pylori: A Randomized Double Blind Placebo Controlled Study

Puram

Suh²,

Kim

et al. 2013

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

A randomized, double blind placebo controlled study was conducted to evaluate the efficacy of GutGard (root extract of Glycyrrhiza glabra) in the management of Helicobacter pylori (H. pylori) gastric load. Participants diagnosed with H. pylori infection were randomly assigned to two groups to orally receive 150 mg of GutGard (n = 55) or placebo (n = 52) once daily for 60 days. H. pylori infection was assessed using 13C-urea breath test (13C-UBT) at days 0, 30, and 60. Stool Antigen test (HpSA) was also performed on days 0, 30, and 60. Repeated measures of analysis of variance (RMANOVA), chi-square, and Fisher's exact probability tests were used to compare the treatment outcomes. A significant interaction effect between group and time (P = 0.00) and significant difference in mean Delta Over Baseline (DOB) values between GutGard (n = 50) and placebo (n = 50) treated groups after intervention period were observed. On day 60, the results of HpSA test were negative in 28 subjects (56%) in GutGard treated group whereas in placebo treated group only 2 subjects (4%) showed negative response; the difference between the groups was statistically significant. On day 60, the results of 13C-UBT were negative in 24 (48%) in GutGard treated group and the difference between the groups was statistically significant. The findings suggest GutGard is effective in the management of H. pylori.

show abstract